No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
GILD Gilead Sciences
- 63.150
- -1.120-1.74%
Close Jun 18 16:00 ET
- 63.220
- +0.070+0.11%
Post 19:58 ET
78.68BMarket Cap175.42P/E (TTM)
64.340High62.685Low6.68MVolume64.170Open64.270Pre Close422.68MTurnover0.54%Turnover Ratio14.03P/E (Static)1.25BShares85.92052wk High4.49P/B78.51BFloat Cap61.31852wk Low3.02Dividend TTM1.24BShs Float89.985Historical High4.78%Div YieldTTM2.58%Amplitude0.409Historical Low63.233Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.69% on an annualized basis producing an average annual return of 10.89%. Currently, Gilead Sciences has a market c
Gilead and Kite Pharma Celebrates Pride Month
NORTHAMPTON, MA / ACCESSWIRE / June 19, 2024 / Gilead SciencesGilead and Kite Pharma teams raised Pride Month flags at our campuses last week symbolizing our united support for LGBTQ+ communities glob
Shareholders in Gilead Sciences (NASDAQ:GILD) Are in the Red If They Invested a Year Ago
Is Gilead Sciences Stock Underperforming the Nasdaq?
Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects
Magrolimab was the centerpiece of Gilead Sciences Inc's (NASDAQ:GILD) $4.9 billion buyout of Forty Seven Inc in March 2020.Magrolimab is a monoclonal antibody targeting CD47 for treating various types
BofA Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $93
BofA Securities analyst Geoff Meacham maintains $Gilead Sciences(GILD.US)$ with a buy rating, and maintains the target price at $93.According to TipRanks data, the analyst has a success rate of 0.0% a
Comments
$Gilead Sciences(GILD.US$
ps: please do your own due diligence before any investing
ps: please do your own due diligence before any investing
1
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
11
2
No megadeals in biotech so far this yr, but on track for record amount >$1 bil deals,
2 biggest deals this yr:
$Vertex Pharmaceuticals(VRTX.US$ paid $4.9 bil for $Alpine Immune(ALPN.US$
$Gilead Sciences(GILD.US$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...
2 biggest deals this yr:
$Vertex Pharmaceuticals(VRTX.US$ paid $4.9 bil for $Alpine Immune(ALPN.US$
$Gilead Sciences(GILD.US$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...
6
Deep-pocketed investors have taken a bullish approach towards $Gilead Sciences(GILD.US$, Benzinga reported, cited nine extraordinary options activities linked to the stock. About 77% of the trades were leaning bullish and 22% bearish, according to the report.
Four of them were puts, totaling $495,628, and five were calls, amounting to $213,111, the report showed. The volume and open interest data on the contract...
Four of them were puts, totaling $495,628, and five were calls, amounting to $213,111, the report showed. The volume and open interest data on the contract...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
